Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1
Bibliographic record
Abstract
Abstract Introduction: The E3 ubiquitin ligase Cbl-b is an intracellular master checkpoint which negatively regulates both adaptive and innate anti-tumor immune responses. Selective targeting of Cbl-b not only induces anti-tumor activity in vivo but also overrides immune regulation by the PD-L1/PD-1 pathway in vitro (2017 Fujiwara et al). Human APN401 is an autologous adoptive cellular therapy of ex vivo Cbl-b-silenced human PBMCs currently in a clinical Phase 1b multiple dose study demonstrating early clinical safety and tolerability in patients with advanced solid tumors. Herein the preclinical Proof of Concept efficacy of murine APN401 immunotherapy is established in the syngeneic mouse hepatocellular carcinoma Hepa1-6 model. Experimental Procedure: Hepa1-6-C57/BL6-tumor bearing mice were treated with murine APN401 ex vivo silenced immune cells with Cbl-b specific siRNA as monotherapy or in combination with anti-PD1 (clone RMP1-14) versus control siRNA. Mice were treated for 14 d starting on D7 after inoculation of Hepa1-6 cells and tumor volume was measured daily. Results: Murine APN401 treatment alone significantly suppressed Hepa1-6 tumor growth by 56% (p<0.0001) versus control siRNA-treated mice. Combination therapy of APN401 with anti-PD1 induced profound synergistic anti-tumor efficacy with tumor growth inhibition of 76% (p<0.0001) versus anti-PD1 alone with control siRNA. APN401 was well tolerated and APN401-treated mice were unremarkable with optimal body conditions. Conclusion: APN401 monotherapy demonstrates striking anti-tumor efficacy in suppressing tumor growth in a murine hepatocellular carcinoma Hepa1-6 model. The preclinical synergistic effects of APN401 with anti-PD1 support its therapeutic utility as a combination therapy with immune checkpoint anti-PD1 treatment. These findings highlight the potential promise of selective Cbl-b silencing by APN401 as a novel immunotherapy for cancer. Citation Format: Anderson Gaweco, Kathrin Thell, Maria Urban, Julia Harrauer, Isabella Haslinger, Alexander Dohnal, Guenther Lametschwandtner, Karin Drobits, Romana Gugenberger, Hannes Muehleisen, Josef Penninger, Carlos Becerra, Vincent Chung, Anthony El-Khoueiry. Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1 [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C048. doi:10.1158/1535-7163.TARG-19-C048
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".